All Posts By

CND Life Sciences

Annovis Bio Completes Dose-Response Study of ANVS401 in Parkinson’s Disease

By In the News

Annovis Bio, Inc., has completed a two-part Phase 2a study of ANVS401 (also known as Posiphen), its investigational treatment for Alzheimer’s and Parkinson’s disease. ANVS401 works by inhibiting the formation of beta-amyloid and tau in Alzheimer’s and alpha-synuclein in Parkinson’s, which differs from other drugs that aim to clear these compounds after they’ve formed.

Read More

Alterity Therapeutics Publishes Pre-Clinical Data for ATH434 in Multiple System Atrophy

By In the News

There are currently no treatments available for multiple system atrophy (MSA), a rare and fatal neurodegenerative disorder caused by the accumulation of alpha-synuclein in the brain. MSA causes problems with movement, balance, and the control of some involuntary bodily functions such as blood pressure and bowel and bladder function. Last month, Alterity Therapeutics published promising results in Movement Disorders of ATH434 in a mouse model of the disease.

Read More

Marcus Neuroscience Institute Offers Syn-One Test™ to Patients

By In the News

Specialized neurologic and neurosurgical care center Marcus Neuroscience Institute, part of Baptist Health South Florida, is now offering its patients the Syn-One Test. Sameea Husain Wilson, D.O., director of Movement Disorder Neurology for the institute, cites the simplicity of administering the test, its high level of accuracy, and the speed with which patients get results as the major benefits of the test.

Read More